Thioflavin derivatives for use in antemortem diagnosis of Alzheimer's disease and in vivo imaging and prevention of amyloid deposition

Patent metadata

Field	Value
Publication number	US-9808541-B2
Application number	US-201414571082-A
Country	US
Kind code	B2
Filing date	Dec 15, 2014
Priority date	Aug 24, 2000
Publication date	Nov 7, 2017
Grant date	Nov 7, 2017

Abstract

This invention relates to novel thioflavin derivatives, methods of using the derivatives in, for example, in vivo imaging of patients having neuritic plaques, pharmaceutical compositions comprising the thioflavin derivatives and method of synthesizing the compounds. The compounds find particular use in the diagnosis and treatment of patients having diseases where accumulation of neuritic plaques are prevalent. The disease states or maladies include but are not limited to Alzheimer's disease, familial Alzheimer's disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

First claim

What is claimed is:

1. A method for detecting amyloid deposits in a subject, comprising the steps of;
(a) administering a detectable quantity of a pharmaceutical composition comprising a compound having a structure selected from the group consisting of:

wherein the compound has at least one substituent selected from the group consisting of 131 I, 125 I, 123 I, 76 Br, 75 Br, and 18 F, and
(b) detecting binding of the compound to amyloid deposits in the subject.

2. The method according to claim 1 , wherein the compound has at least one substituent that is 131 I.

3. The method according to claim 1 , wherein the compound as at least one substituent that is 125 I.

4. The method according to claim 1 , wherein the compound has at least one substituent that is 123 I.

5. The method according to claim 1 , wherein the compound has at least one substituent that is 76 Br.

6. The method according to claim 1 , wherein the compound has at least one substituent that is 75 Br.

7. The method according to claim 1 , wherein with the compound has at least one substituent that is 18 F.

8. The method according to claim 1 , wherein the amyloid deposits are located in the brain of a subject.

9. The method according to claim 1 , wherein the subject is suspected of having a disease or syndrome selected from the group consisting of Alzheimer's Disease, familial Alzheimer's Disease, Down's Syndrome and homozygotes for the apolipoprotein E4 allele.

10. The method according to claim 1 , wherein the detecting is achieved by positron emission tomography.

11. The method according to claim 1 , wherein the pharmaceutical composition is administered by intravenous injection.

12. The method according to claim 1 , wherein the ratio of (i) binding of the compound to a brain area other than the cerebellum to (ii) binding of the compound to the cerebellum in the subject is compared to the ratio in a normal subject.

13. A method of detecting amyloid deposits in biopsy or post-mortem human or animal tissue comprising the steps of:
(a) incubating formalin-fixed or fresh-frozen tissue with a solution of an amyloid binding compound to form labeled deposits, wherein the compound has a structure selected from the group consisting of:

wherein the compound has at least one substituent selected from the group consisting of 131 I, 125 I, 76 Br, 75 Br, and 18 F; and
(b) detecting the labeled deposits.

14. The method according to claim 13 , wherein the solution is composed of 25-100% ethanol, with the remainder of the solution being water, wherein the solution is saturated with the compound.

15. The method according to claim 13 , wherein the solution is composed of an aqueous buffer containing 0-50% ethanol, and wherein the solution contains 0.0001 to 100 μM of the compound.

16. The method according to claim 13 , wherein the detecting is effected by microscopic techniques selected from the group consisting of bright-field, fluorescence, laser-confocal, and cross-polarization microscopy.

17. A method of selectively binding a compound to amyloid plaques over neurofibrillary tangles in in vivo brain tissue which comprises both, wherein the compound has a structure selected from the group consisting of:

wherein the compound has at least one substituent selected from the group consisting of 131 I, 125 I, 123 I, 76 Br, 75 Br, and 18 F,
comprising administering to a subject in need an effective amount of the compound so that blood concentration of the administered compound remains below 10 nM in vivo.

Assignees

• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Education
• Univ Of Pittsburgh—Of The Commonwealth System Of Higher Eduation

Inventors

• Klunk William E
• Mathis Jr Chester A
• Wang Yanming

Classifications

• G01N33/6896

  Neurological disorders, e.g. Alzheimer's disease · CPC title

• C07B2200/05

  Isotopically modified compounds, e.g. labelled · CPC title

• G01N2800/387

  Down syndrome; Trisomy 18; Trisomy 13 · CPC title

• A61K51/0453 Primary

  having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole · CPC title

• A61K51/0497

  conjugates with a carrier being an organic compounds · CPC title